Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis

  • Melf Jakob Kühl
  • , Thandile Gondwe
  • , Aggrey Dhabangi
  • , Titus K. Kwambai
  • , Amani T. Mori
  • , Robert Opoka
  • , C. Chandy John
  • , Richard Idro
  • , Feiko O. ter Kuile
  • , Kamija S. Phiri
  • , Bjarne Robberstad

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Background: Children hospitalised with severe anaemia in malaria-endemic areas are at a high risk of dying or being readmitted within six months of discharge. A trial in Kenya and Uganda showed that three months of postdischarge malaria chemoprevention (PDMC) with monthly dihydroartemisinin-piperaquine (DP) substantially reduced this risk. The World Health Organization recently included PDMC in its malaria chemoprevention guidelines. We conducted a cost-effectiveness analysis of community-based PDMC delivery (supplying all three PDMC-DP courses to caregivers at discharge to administer at home), facility-based PDMC delivery (monthly dispensing of PDMC-DP at the hospital), and the standard of care (no PDMC). Methods: We combined data from two recently completed trials; one placebo-controlled trial in Kenya and Uganda collecting efficacy data (May 6, 2016 until November 15, 2018; n=1049), and one delivery mechanism trial from Malawi collecting adherence data (March 24, 2016 until October 3, 2018; n=375). Cost data were collected alongside both trials. Three Markov decision models, one each for Malawi, Kenya, and Uganda, were used to compute incremental cost-effectiveness ratios expressed as costs per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analyses were performed to account for uncertainty. Findings: Both PDMC strategies were cost-saving in each country, meaning less costly and more effective in increasing health-adjusted life expectancy than the standard of care. The estimated incremental cost savings for community-based PDMC compared to the standard of care were US$ 22·10 (Malawi), 38·52 (Kenya), and 26·23 (Uganda) per child treated. The incremental effectiveness gain using either PDMC strategy varied between 0·3 and 0·4 QALYs. Community-based PDMC was less costly and more effective than facility-based PDMC. These results remained robust in sensitivity analyses. Interpretation: PDMC under implementation conditions is cost-saving. Caregivers receiving PDMC at discharge is a cost-effective delivery strategy for implementation in malaria-endemic southeastern African settings. Funding: Research Council of Norway.

Original languageEnglish (US)
Article number101669
JournaleClinicalMedicine
Volume52
DOIs
Publication statusPublished - Oct 2022
Externally publishedYes

Keywords

  • Adherence
  • Children under five years of age
  • Cost-effectiveness analysis
  • DP
  • Dihydroartemisinin-piperaquine
  • Economic evaluation
  • IPTpd
  • Intermittent preventive therapy
  • Kenya
  • Malaria prophylaxis
  • Malawi
  • PDMC
  • PMC
  • Post-discharge
  • Postdischarge
  • Preschool children
  • Severe anaemia
  • Sub-Saharan Africa
  • Uganda
  • malaria chemoprevention
  • malaria prevention

Fingerprint

Dive into the research topics of 'Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis'. Together they form a unique fingerprint.

Cite this